GERON CORP (GERN) Stock Price, Quote, News and Overview
NASDAQ:GERN - Nasdaq - US3741631036 - Common Stock - Currency: USD
GERN Quote, Performance and Key Statistics
1.45
0 (0%)
The current stock price of GERN is 1.45 USD. In the past month the price increased by 16.94%. In the past year, price decreased by -67.78%.
GERN Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 19.52 | 365.10B | ||
| AMGN | AMGEN INC | 13.59 | 159.41B | ||
| GILD | GILEAD SCIENCES INC | 15.29 | 147.24B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 23.19 | 100.87B | ||
| REGN | REGENERON PHARMACEUTICALS | 12.72 | 62.67B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 58.53B | ||
| ARGX | ARGENX SE - ADR | 70.53 | 40.01B | ||
| ONC | BEONE MEDICINES LTD-ADR | 5.92 | 34.78B | ||
| BNTX | BIONTECH SE-ADR | N/A | 27.29B | ||
| INSM | INSMED INC | N/A | 24.24B | ||
| NTRA | NATERA INC | N/A | 22.26B | ||
| BIIB | BIOGEN INC | 8.66 | 20.31B |
Related stock screener links
About GERN
Company Profile
Geron Corp. operates as a biotechnology company. The company is headquartered in Foster City, California and currently employs 229 full-time employees. The firm develops first-in-class telomerase inhibitor, RYTELO (imetelstat) for the treatment of adult patients with low- to intermediate-1 risk myelodysplastic syndromes (lower-risk MDS), with transfusion-dependent (TD) anemia requiring four or more red blood cell units over eight weeks who have not responded to or have lost response to or are ineligible for erythropoiesis-stimulating agents (ESAs). RYTELO is supported by the high unmet need in lower-risk MDS, including the observed benefit of RYTELO in difficult-to-treat subpopulations, such as patients with high transfusion burden and ring sideroblast negative (RS-) patients. The company is also engaged in conducting a pivotal Phase III clinical trial of imetelstat in JAK-inhibitor relapsed/refractory myelofibrosis (R/R MF), as well as studies in other myeloid hematologic malignancies.
Company Info
GERON CORP
919 East Hillsdale Boulevard, Suite 250
Foster City CALIFORNIA 94404 US
CEO: John A. Scarlett
Employees: 229
Phone: 16504737700
GERON CORP / GERN FAQ
What is the stock price of GERON CORP today?
The current stock price of GERN is 1.45 USD.
What is the ticker symbol for GERON CORP stock?
The exchange symbol of GERON CORP is GERN and it is listed on the Nasdaq exchange.
On which exchange is GERN stock listed?
GERN stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for GERON CORP stock?
16 analysts have analysed GERN and the average price target is 3.46 USD. This implies a price increase of 138.39% is expected in the next year compared to the current price of 1.45. Check the GERON CORP stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is GERON CORP worth?
GERON CORP (GERN) has a market capitalization of 923.53M USD. This makes GERN a Small Cap stock.
How many employees does GERON CORP have?
GERON CORP (GERN) currently has 229 employees.
What are the support and resistance levels for GERON CORP (GERN) stock?
GERON CORP (GERN) has a support level at 1.45 and a resistance level at 1.61. Check the full technical report for a detailed analysis of GERN support and resistance levels.
Is GERON CORP (GERN) expected to grow?
The Revenue of GERON CORP (GERN) is expected to grow by 162.93% in the next year. Check the estimates tab for more information on the GERN EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy GERON CORP (GERN) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of GERN, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of GERN, evaluating the profitability, health, valuation and growth aspects
- GERON CORP (GERN) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- GERON CORP (GERN) Sales and EPS estimates to see what analysts future expectations are.
- GERON CORP (GERN) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- GERON CORP (GERN) Insider and Institutional Ownership to learn about the owners and their transactions.
- GERON CORP (GERN) Stock Chart to make your own analysis
- GERON CORP (GERN) Latest news and press-releases to stay up to date.
Does GERON CORP (GERN) stock pay dividends?
GERN does not pay a dividend.
When does GERON CORP (GERN) report earnings?
GERON CORP (GERN) will report earnings on 2025-11-05, before the market open.
What is the Price/Earnings (PE) ratio of GERON CORP (GERN)?
GERON CORP (GERN) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.13).
What is the Short Interest ratio of GERON CORP (GERN) stock?
The outstanding short interest for GERON CORP (GERN) is 10.68% of its float. Check the ownership tab for more information on the GERN short interest.
GERN Technical Analysis
ChartMill assigns a technical rating of 2 / 10 to GERN. When comparing the yearly performance of all stocks, GERN is a bad performer in the overall market: 91.82% of all stocks are doing better.
GERN Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to GERN. While GERN seems to be doing ok healthwise, there are quite some concerns on its profitability.
GERN Financial Highlights
Over the last trailing twelve months GERN reported a non-GAAP Earnings per Share(EPS) of -0.13. The EPS increased by 63.89% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -15.85% | ||
| ROE | -33.91% | ||
| Debt/Equity | 0.46 |
GERN Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 79% to GERN. The Buy consensus is the average rating of analysts ratings from 16 analysts.
For the next year, analysts expect an EPS growth of 52.14% and a revenue growth 162.93% for GERN